hummm,,,I am not sure about the suggestion here that this management team cant manage some relatively simple math around enrollment, events, time overall, adjudication and the tally!,,,when we have access to computerized data analysis for end of trial,,,, so if they can figure out the slant on epigenetics and the MOA of their 208 molecule I think it is an embarrassment to think they have limited understanding around the probable event target numbers and timing in BoM.

It is more reasonable to assume these adjudicated event numbers are delayed by simply the unexpected lack of events which plays into the meet and exceed side of the RRR%,,,cuz the placebo group should have been very easily given an approximate event number based on the design data driving this trial!! If that is untrue then the trial design created by this management team is nothing more and should be understood to be amateur at best. jmo